Topic: sterile injectables
Swedish CDMO Recipharm has decided to buy the piece of Indian sterile drugmaker Nitin Lifesciences that it doesn’t currently own.
A U.S. unit of Japan’s Daiichi Sankyo that makes sterile injectable drugs will invest $145 million to expand facilities in Ohio, adding 80 jobs in the process.
Xellia Pharmaceuticals is hiring at the former Ben Venue Labs in Bedford, Ohio, as it prepares to begin drug manufacturing at the site next year.
With plans for a major expansion of its site North Carolina, Fresenius Kabi's investments aimed mainly at the U.S. generics market now top $5 billion.
AmerisourceBergen has added $50 million more to resolve a DOJ probe into sales of cancer meds, taking its total in the matter to $885 million.
Manufacturing issues at legacy Hospira plants have taken a toll on Pfizer’s earnings and created serious problems for some of its clients.
An Akorn sterile drug plant is in hot water with the FDA again, but it may be a problem for Fresenius Kabi, which is buying the generics manufacturer.
Xellia Pharmaceuticals is investing $25 million to build additional sterile manufacturing capacity at its site in Copenhagen.
AmerisourceBergen has pled guilty and agreed to pay $260 million to settle a federal case over its sales of cancer meds from an unregistered facility.
Fresenius Kabi, which has been spending heavily to broaden its capabilities, has started construction on a $250 million project in Illinois.